Felix currently serves as President and CEO of Boehringer Ingelheim Greater China. He joined Boehringer Ingelheim in 1997 and has held various financial management positions in Italy, Mexico and Germany. As a seasoned industry leader with extensive cross-functional and cross-business expertise, Felix has been driving innovative development of Boehringer Ingelheim in China since 2019. Under his leadership, the company has introduced a stream of novel businesses and products, and forged multiple innovative partnerships, which have significantly improved not only the company’s market presence in China, but also the strategic position of the Chinese market on the global scale.
Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Venus MedTech (HKSE:2500) among others. Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606)among others. Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China (#1 in 2022). She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of HKEX and Hong Kong Palace Museum.
Thomas is Head of Group Innovation Technology Fields at the Merck Group Science and Technology Office. He leads the key innovation projects, collaborations in important innovation regions, and critical programs that support the innovation priorities of Merck. In 2004, he joined Merck Group in Germany and led large global R&D teams. In 2017, he became Head of Merck Silicon Valley Innovation Hub. In 2021, he also became Head of China Innovation Hub. Thomas is a member of Merck's Innovation Steering Committee and Merck's Ethics Advisory Panel; Chairman of Merck's Stem Cell Research Oversight Committee; Director of the Technology Development Council (UCLA) and Center of Wearable Sensors (USCD), and a professor for new technologies for pharmaceutical research. He has won multiple awards and published more than 70 peer-reviewed papers and 25 patents.
Jin is a Senior Partner at McKinsey & Company. She joined the Firm in 2003 and leads McKinsey’s Greater China‘s healthcare practice. Jin advises global and Chinese healthcare providers, health insurance companies and pharma companies on a broad range of topics, including growth strategy, operations transformations, and business model innovation. She also helped companies build healthcare ecosystem enabled by digital and technology. Jin is a co-author of McKinsey whitepapers, "China Healthcare – Entering uncharted waters", “Finding the future of care provision, the role of hospitals”, and "Evolution of digital hospital in China".
Gil is Chair Global Health and Purpose at FINN Partners and has held leadership positions with New York-based agencies Makovsky and Hill & Knowlton and at pioneering integrated health-marketing agency Sutton Healthcare Group (acquired by Medicus). He was Group Company CEO, CommonHealth, a WPP Group Company. He served as CEO of Health!Quest Global Communication Partners is a GTCR-backed private-equity firm with more than $10 billion in active assets. Gil has been tapped by PharmaVOICE "as one of the 100 most inspiring people in healthcare.” He serves as a Galien Foundation Committee Chair for the Incubator, Accelerator and Private Equity Prix Galien Prize and corporate advisory boards in the health innovation sector.
Before joining CEIBS, Terry was Associate Professor of Entrepreneurship at IE Business School in Spain. He also worked for multinational corporations and governmental organizations before pursuing his academic career. Terry teaches Entrepreneurial Management and New Venture Growth at the MBA and EMBA levels. Terry’s research has appeared in numerous journals, including Academy of Management Journal, Strategic Management Journal, Strategic Entrepreneurship Journal, Research Policy, and Human Relations. He currently serves as an editorial board member of Journal of Business Ethics.
Eric received his Ph.D. in Organisational Sociology from the National Institute of Oriental Languages and Civilizations in France. Before joining CEIBS, he was General Manager of Ipsen China (2001–2011), then Senior Vice President for Asia Operations leading Asian markets for Consumer HealthCare (2012-2017). In 1989, he joined HEC Eurasia Institute, a think tank of the HEC School of Management, and became Deputy Director in 1990. Eric served as Vice Chairman (2011-2015), then Chairman (2016-2017) of the ‘Research & Development based Pharmaceutical Association in China’ (RDPAC).